Johnson & Johnson (JNJ) Releases FY16 Earnings Guidance
Johnson & Johnson (NYSE:JNJ) updated its FY16 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $6.68-6.73 for the period, compared to the Thomson Reuters consensus estimate of $6.69. The company issued revenue guidance of $71.5-72.2 billion, compared to the consensus revenue estimate of $72.14 billion.
A number of analysts have weighed in on the company. Zacks Investment Research upgraded Johnson & Johnson from a hold rating to a buy rating and set a $139.00 price target for the company in a report on Friday, August 5th. BMO Capital Markets reiterated an outperform rating and set a $132.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 20th. Deutsche Bank AG reiterated a hold rating and set a $142.00 price target (up from $125.00) on shares of Johnson & Johnson in a report on Thursday, July 21st. Vetr upgraded Johnson & Johnson from a sell rating to a hold rating and set a $124.21 price target for the company in a report on Monday, August 8th. Finally, BTIG Research restated a neutral rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $120.20.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 118.49 on Tuesday. Johnson & Johnson has a 12-month low of $94.28 and a 12-month high of $126.07. The company has a market cap of $324.17 billion, a PE ratio of 22.08 and a beta of 0.62. The company has a 50 day moving average of $118.71 and a 200-day moving average of $117.56.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.03. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The firm earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same period in the previous year, the business posted $1.49 EPS. The business’s revenue was up 4.2% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post $6.69 earnings per share for the current year.
In related news, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of JNJ. Horizon Investments LLC boosted its position in Johnson & Johnson by 0.3% in the second quarter. Horizon Investments LLC now owns 2,349 shares of the company’s stock worth $285,000 after buying an additional 8 shares in the last quarter. Lbmc Investment Advisors LLC boosted its position in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $457,000 after buying an additional 16 shares in the last quarter. Kinsight LLC boosted its position in Johnson & Johnson by 0.5% in the second quarter. Kinsight LLC now owns 3,891 shares of the company’s stock worth $472,000 after buying an additional 21 shares in the last quarter. Greenwich Wealth Management LLC boosted its position in Johnson & Johnson by 1.1% in the second quarter. Greenwich Wealth Management LLC now owns 2,494 shares of the company’s stock worth $303,000 after buying an additional 27 shares in the last quarter. Finally, Northeast Financial Consultants Inc boosted its position in Johnson & Johnson by 0.3% in the second quarter. Northeast Financial Consultants Inc now owns 14,992 shares of the company’s stock worth $1,819,000 after buying an additional 40 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.